In the last trading session, 2.13 million Amylyx Pharmaceuticals Inc (NASDAQ:AMLX) shares changed hands as the company’s beta touched -0.50. With the company’s per share price at $6.41 changed hands at $0.08 or 1.26% during last session, the market valuation stood at $571.39M. AMLX’s last price was a discount, traded about -13.42% off its 52-week high of $7.27. The share price had its 52-week low at $1.62, which suggests the last value was 74.73% up since then. When we look at Amylyx Pharmaceuticals Inc’s average trading volume, we note the 10-day average is 2.64 million shares, with the 3-month average coming to 1.20 million.
Analysts gave the Amylyx Pharmaceuticals Inc (AMLX) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.12. If we narrow down to specifics, the data shows that 0 out of 3 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended AMLX as a Hold, 3 felt it is a Buy and 0 rated the stock as Underweight.
Amylyx Pharmaceuticals Inc (NASDAQ:AMLX) trade information
Instantly AMLX was in green as seen at the end of in last trading. With action 27.69%, the performance over the past five days has been green. The company’s shares are showing year-to-date upside of 250.27%, with the 5-day performance at 27.69% in the green. However, in the 30-day time frame, Amylyx Pharmaceuticals Inc (NASDAQ:AMLX) is 30.82% up. Looking at the short shares, we see there were 4.04 million shares sold at short interest cover period of 4.43 days.
The consensus price target for the stock as assigned by Wall Street analysts is 13.5, meaning bulls need an upside of 52.52% from its current market value. According to analyst projections, AMLX’s forecast low is 10 with 17 as the target high. To hit the forecast high, the stock’s price needs a -165.21% plunge from its current level, while the stock would need to soar -56.01% for it to hit the projected low.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of -78.71%. The 2025 estimates are for Amylyx Pharmaceuticals Inc earnings to increase by 59.46%, but the outlook for the next 5-year period is at 29.78% per year.
AMLX Dividends
Amylyx Pharmaceuticals Inc is expected to release its next quarterly earnings report on 2025-May-08.
Amylyx Pharmaceuticals Inc (NASDAQ:AMLX)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 12.47% of Amylyx Pharmaceuticals Inc shares while 85.88% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 98.11%. There are 85.88% institutions holding the Amylyx Pharmaceuticals Inc stock share, with VANGUARD GROUP INC the top institutional holder. As of 2024-06-30, the company held 6.2094% of the shares, roughly 4.22 million AMLX shares worth $8.03 million.
AQR CAPITAL MANAGEMENT LLC holds the second largest percentage of outstanding shares, with 4.9114% or 3.34 million shares worth $6.35 million as of 2024-06-30.
Among Mutual Funds, the top two as of Mar 31, 2025 were VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and abrdn Healthcare Investors . With 2.3 shares estimated at $14.73 million under it, the former controlled 2.58% of total outstanding shares. On the other hand, abrdn Healthcare Investors held about 1.89% of the shares, roughly 1.69 shares worth around $10.82 million.
